Results 191 to 200 of about 19,342 (221)
Some of the next articles are maybe not open access.
Novel Delivery of Antiarrhythmic Agents
Clinical Pharmacokinetics, 1995Conventional antiarrhythmia therapy by oral or intravenous routes of administration is often ineffective and results in drug-associated complications and toxicity. In addition, poor bioavailability and a high first-pass effect limit therapeutic applications of several investigational antiarrhythmic compounds, which are otherwise more potent and less ...
V, Labhasetwar, R J, Levy
openaire +2 more sources
Flecainide: A new antiarrhythmic agent
American Heart Journal, 1986PVCs (trigger mechanisms) and the vulnerability of the myocardium to sustain a life-threatening ventricular tachycardia (substrate) are two variables in the sudden death equation. Physicians treating patients at risk for sudden death should consider PVC frequency and vulnerability as interrelated variables.
J C, Somberg, D, Tepper
openaire +2 more sources
Encainide: A New Antiarrhythmic Agent
Drug Intelligence & Clinical Pharmacy, 1986Encainide is classified as a type Ic antiarrhythmic agent. Absorption is essentially complete, but bioavailability is variable because of first-pass metabolism. Two metabolic phenotypes, extensive and poor metabolizers, have been identified. O-demethyl encainide and 3-methoxy-O-demethyl encainide are active metabolites of encainide and contribute ...
A E, Wehmeyer, R L, Thomas
openaire +2 more sources
1989
The drug therapy of arrhythmias has developed rapidly over the last 25 years. During this period, the number of available antiarrhythmic agents has increased dramatically and many more compounds are in development. In the United Kingdom there are more than forty antiarrhythmic drugs (including beta adrenergic blocking agents) currently listed in the ...
A. John Camm, Nicholas J. Linker
openaire +1 more source
The drug therapy of arrhythmias has developed rapidly over the last 25 years. During this period, the number of available antiarrhythmic agents has increased dramatically and many more compounds are in development. In the United Kingdom there are more than forty antiarrhythmic drugs (including beta adrenergic blocking agents) currently listed in the ...
A. John Camm, Nicholas J. Linker
openaire +1 more source
Propranolol as an antiarrhythmic agent
American Heart Journal, 1967Abstract While additional studies will be needed to clarify the role of propranolol and other beta-adrenergic blocking agents, they are important therapeutic supplements to the treatment of specific cardiac arrhythmias. They are hazardous if the clinician is not familiar with their physiologic effects.
openaire +2 more sources
Dronedarone: A new antiarrhythmic agent
Drugs of Today, 2006Dronedarone (SR 33589; N,N-dibutyl-3-[4-([2-butyl-5-methylsulphonamido] benzofuran-3-yl-carbonyl) phenoxy]propylamine) is a new synthetic noniodinated derivative of amiodarone that is currently undergoing phase III clinical trials. It demonstrates electrophysiologic patterns similar to amiodarone and shows equivalent efficacy in preventing or ...
openaire +2 more sources
Differential Utility of Antiarrhythmic Agents
Cardiology, 1987Sudden cardiac death (SCD), which is recognized as the most common cause of death in adults, in 80% of cases results from a ventricular tachyarrhythmia that subsequently degenerates into ventricular fibrillation. Ventricular arrhythmias have been identified as a major factor in predicting a high risk of SCD and can be classified as benign, potentially ...
openaire +2 more sources